Veno-occlusive disease with multi-organ involvement following actinomycin-D

European Journal of Cancer

Volumn 37, Issue 9, 2001, Pages 1141-1148

  Verdecchia, A ^a   Mariotto, A ^a   Capocaccia, R ^a   Gatta, G ^b   Micheli, A ^b   Sant, M ^b   Berrino, F ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Actinomycin D; Children; Multi organ failure; Veno occlusive disease; Wilms' tumour

Indexed keywords

ALTEPLASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; DACTINOMYCIN; DOXORUBICIN; FIBRINOGEN; FIBRINOGEN DEGRADATION PRODUCT; GAMMA GLUTAMYLTRANSFERASE; HEPARIN; THROMBOCYTE ANTIBODY; TISSUE PLASMINOGEN ACTIVATOR; VINCRISTINE;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; ARTIFICIAL VENTILATION; ASCITES; BRAIN DISEASE; CANCER LOCALIZATION; CANCER STAGING; CLEAR CELL SARCOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; HEMOFILTRATION; HEPATOMEGALY; HUMAN; INFANT; KIDNEY DISEASE; LIVER DYSFUNCTION; MALE; MULTIPLE ORGAN FAILURE; NEPHROBLASTOMA; NEUTROPENIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RHABDOMYOSARCOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; VEIN OCCLUSION;

ANTIBIOTICS, ANTINEOPLASTIC; CHILD, PRESCHOOL; CONSTRICTION, PATHOLOGIC; DACTINOMYCIN; HUMANS; INFANT; KIDNEY NEOPLASMS; MALE; MULTIPLE ORGAN FAILURE; RHABDOMYOSARCOMA; TESTICULAR NEOPLASMS; VASCULAR DISEASES; WILMS TUMOR;

EID: 0035005246     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00097-1     Document Type: Article

References (43)

1. Veno-occlusive disease of the liver with nonportal type of cirrhosis, occurring in Jamaica
2. Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: Incidence, risk factors, and clinical outcome
3. Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia
4. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients
5. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia
6. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: A study in 136 children
7. Veno-occlusive disease of the liver following high-dose chemotherapy and autologous bone marrow transplantation in children with solid tumors: Incidence, clinical course and outcome
8. Veno-occlusive disease of the liver after allogenic bone marrow transplantation in children with hematologic malignancies: Incidence, onset time and risk factors
9. Severe hepatic toxicity after treatment with single-dose dactinomycin and vincristine: A report of the National Wilms' Tumor Study
10. Severe hepatic toxicity after treatment with vincristine and dactinomycin using single-dose or divided dose schedules: A report from the National Wilms' Tumor Study
11. Hepatotoxicity and actinomycin-D
12. Hepatotoxicity and actinomycin D
13. Hepatotoxicity of actinomycin-D
14. Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma. A report of the Intergroup Rhabdomyosarcoma Study Group
15. Veno-occlusive disease of the liver after combined adjuvant chemotherapy for a 1-year-old boy with rhabdomyosarcoma: Potential usefulness of the gabexate mesylate (FOY)
16. Veno-occlusive disease with fibrinolysis as the cause of death during preoperative chemotherapy for nephroblastoma
17. Hepatotoxicity of chemotherapy following nephrectomy and radiation therapy for right-sided Wilms' Tumor
18. Hepatotoxicity in irradiated nephroblastoma patients during postoperative treatment according to SIOP9/GPOH
19. Veno-occlusive disease-like hepatotoxicity in two children receiving chemotherapy for Wilms' tumor and clear cell sarcoma of kidney
20. Veno-occlusive disease of the liver in children treated for Wilms tumor
21. Hepatopathy-thrombocytopenia syndrome - A complication of dactinomycin therapy for Wilms' Tumor: A report from the United Kingdom Childrens Cancer Study Group
22. Veno-occlusive disease of the liver in right-sided Wilms' tumours
23. Actinomycin D, hepatic toxicity and Wilms' tumour - A mystery explained?
24. Hepatotoxicity in patients treated according to the nephroblastoma trial and study SIOP-9/GPOH
25. Venocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors
26. High plasma levels of tumor necrosis factor-α may be predictive of veno-occlusive disease in bone marrow transplantation
27. Naturally occurring anticoagulants after bone marrow transplantation: Plasma protein C predicts the development of venocclusive disease of the liver
28. Serum levels of cytokines after bone marrow transplantation: Increased IL-8 levels during severe veno-occlusive disease of the liver
29. Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers
30. The relevance of plasminogen activator inhibitor 1 (PAI-1) as a marker for the diagnosis of hepatic veno-occlusive disease in patients after bone marrow transplantation
31. Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: A prospective study
32. Thrombocytopenia in veno-occlusive disease after bone marrow transplantation or chemotherapy
33. Increased platelet transfusion requirement is associated with multiple organ dysfunctions in patients undergoing hematopoietic stem cell transplantation
34. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low dose heparin. A prospective, randomized trial
35. Hepatic veno-occlusive disease in pediatric stem cell recipients: Successful treatment with continuos infusion of prostaglandin E1 and low-dose heparin
36. Defibrotide as salvage therapy for refractory veno-occlusive disease of the liver complicating allogeneic bone marrow transplantation
37. Antithrombin treatment of severe hepatic veno-occlusive disease in children with cancer
38. Veno-occlusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator
39. Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD)
40. No beneficial effects, but severe side effects caused by recombinant human tissue plasminogen activator for treatment of hepatic veno-occlusive disease after allogeneic bone marrow transplantation
41. Recombinant tissue plasminogen activator (rt-PA) for veno-occlusive liver disease in pediatric autologous bone marrow transplant patients
42. Fulminant hepatic failure: Pediatric aspects
43. Successful treatment of hepatic venocclusive disease in a bone marrow transplant patient with orthotopic liver transplantation